Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/222773
Title: | Organizing pneumonia in hospitalized COVID-19 patients: risk factors and long-term outcomes |
Author: | Cuerpo, Sandra Hernandez-gonzalez, Fernanda Benegas, Mariana Albacar, Nuria Lopez-giraldo, Alejandra Cobo, Inés Suarez, Samara Torres, Verónica Salazar, Adelaido Soler, Nestor Noboa-sevilla, María Frino-garcía, Alejandro Pérez-rodas, Nancy Francesqui, Joel Alsina-restoy, Xavier María Muñoz Fernández, Ana Roger, Nuria Prieto, Sergio Vlagea, Alexandru Ruiz, Estibaliz Faner, Rosa Albert Barberà, Joan Soriano, Alex Ramon Badia, Joan Molina-molina, María Sibila, Oriol Sánchez, Marcelo Agustí, Alvar Garcia-aymerich, Judith Sellares, Jacobo |
Issue Date: | 4-Jul-2025 |
Publisher: | Springer Science and Business Media LLC |
Abstract: | Background Some patients develop post-COVID-19 organizing pneumonia (OP) that is responsive to corticosteroid treatment. This multicenter, case-control study of patients hospitalized for COVID-19 sought to determine the prevalence, risk factors, radiological outcomes, and evolution after treatment. Methods We included 153 consecutive patients with OP and 140 without OP who required hospitalization because of COVID-19 from February to April 2020. OP patients were followed up for 12 months, with visits at 1, 3, 6, and 12 months after hospital discharge. Results Risk factors for OP at hospital admission were advanced age, previous respiratory disease, and elevated C-reactive protein levels. Follow-up computed thoracic (CT) scans performed one year after admission showed progressive improvement in radiological involvement; however, up to 57% of patients with OP remained with fibrotic-like changes. Multivariate analysis showed a significant association of fibrotic pattern with older age, high dose of corticosteroids, and extensive parenchymal lung involvement on admission CT scans. Conclusions Following COVID-19 OP, fibrotic-like changes may persist over the long term. Higher dose of corticosteroids does not seem to be associated with a better prognosis. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s41479-025-00169-9 |
It is part of: | Pneumonia, 2025, vol. 17, issue. 1 |
URI: | https://hdl.handle.net/2445/222773 |
Related resource: | https://doi.org/10.1186/s41479-025-00169-9 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s41479-025-00169-9.pdf | 1.62 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.